LOGIN  |  REGISTER
Recursion
Cue Biopharma

Tactile Medical to Present at the 2023 Wells Fargo Healthcare Conference

August 31, 2023 | Last Trade: US$22.01 6.24 39.57

MINNEAPOLIS, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the 2023 Wells Fargo Healthcare Conference, which is being held at the Encore Boston Harbor in Boston, MA from September 6th - 8th. Management will participate in a fireside chat on Thursday, September 7th at 8:45 a.m. Eastern Time.

A live audio webcast of the fireside chat will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the webcast will be available for replay following the conference.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Viking Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page